- Thermo Fisher Scientific Inc. (TMO, Financial) reported Q1 2025 revenue of $10.36 billion, with a GAAP EPS increase of 15% to $3.98.
- The company executed a $4.1 billion acquisition of Solventum's business and repurchased $2.0 billion in stock.
- New product launches include the Vulcan Automated Lab for semiconductor analysis and energy-saving centrifuges.
Thermo Fisher Scientific Inc. (TMO), a global leader in scientific services, announced robust financial results for the first quarter of 2025. The company achieved a revenue of $10.36 billion, reflecting a slight increase from $10.34 billion in the corresponding quarter of 2024. GAAP diluted earnings per share (EPS) saw a significant rise of 15%, reaching $3.98.
Adjusted EPS increased modestly by 1% to $5.15, highlighting the company’s stable financial footing amid challenging economic conditions. Thermo Fisher reported a 1% organic revenue growth, with its GAAP operating margin improving to 16.6% from 16.1% in the previous year.
Demonstrating its continued commitment to strategic investments and shareholder returns, Thermo Fisher agreed to acquire Solventum’s Purification & Filtration Business for $4.1 billion in cash. The company also repurchased $2.0 billion worth of stock and raised its dividend by 10% during the first quarter.
Innovative product releases were at the forefront of Thermo Fisher’s growth strategy. New launches include the Thermo Scientific™ Vulcan™ Automated Lab, designed to enhance semiconductor productivity with advanced AI and electron microscopy integration, and new proteomics kits under its Olink® Reveal brand for identifying inflammation-related proteins.
Thermo Fisher’s (TMO, Financial) management emphasized their reliance on the proprietary PPI Business System to drive operational excellence and support customer success, ensuring they remain well-positioned to navigate the current macroeconomic environment and continue creating value for stakeholders.
